8-10 November, 2024

Cleveland Clinic Abu Dhabi, UAE

Countdown Expired!

Dr. Mahdi Shkoukani

Department Chairman
Otolaryngology (ENT) and Head & Neck Surgery
Surgical Subspecialties Institute
Cleveland Clinic Abu Dhabi

WELCOME TO THE CLEVERAD 2024

As the Chairman of this year's event, I am profoundly honored to extend a warm welcome to each of you joining us in person. This year, we have curated an enriching program that underscores the strides we have made in the fight against thyroid cancer, as well as the challenges that lie ahead.

In an era marked by rapid advancements in medical science, the significance of staying abreast with the latest research, treatments, and diagnostic approaches cannot be overstated. Thyroid Cancer Update 2024 is designed to foster an environment of learning, sharing, and collaboration among the brightest minds in the field—from seasoned experts to emerging talents.

Our agenda is packed with insightful presentations, and stimulating discussions, all aimed at enhancing our collective expertise and ultimately improving patient outcomes. We are united by a common goal: to push the boundaries of what's possible in thyroid cancer care.

I invite you to immerse yourself in the opportunities that Thyroid Cancer Update 2024 presents. Your participation is not just a testament to your commitment to excellence in healthcare but also a vital contribution to our shared mission of making a tangible difference in the lives of those affected by thyroid cancer.

Let's embark on this journey together, inspired by the knowledge that our collective efforts will continue to shape a brighter future for thyroid cancer care.

Conference Objectives

Discuss updates for the diagnosis and management of thyroid cancer, especially the use of molecular genomics to provide targeted tyrosine kinase inhibitor therapy.

Target Audience

Disclosure and Conflict of Interest

The planning committee, faculty and others in control of content (either individually or as a group) do not have relevant financial relationships with ineligible companies.